9926:HKG
Akeso Inc
91,30 HK$
arrow_upward
+0,94%(+0,85) 1D
16 қаз., 16:08:14 GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 9926...
Open
92,15 HK$
High
95,30 HK$
Low
90,15 HK$
Mkt. cap
84,10 млрд
Avg. vol.
10,45 млн
Volume
11,09 млн
52-wk high
156,00 HK$
52-wk low
80,20 HK$
EPS
-1,24 HK$
No. of employees
4 мың
Open
92,15 HK$
High
95,30 HK$
Low
90,15 HK$
Mkt. cap
84,10 млрд
Avg. vol.
10,45 млн
Volume
11,09 млн
52-wk high
156,00 HK$
52-wk low
80,20 HK$
EPS
-1,24 HK$
No. of employees
4 мың
News stories
From web sources and news partners
Simply Wall Street
·
1 сағат бұрын
Is Akeso (SEHK:9926) Undervalued On Its Phase III Colon Cancer Trial News?
Yahoo Finance
·
1 күн бұрын
Will Phase III Colon Cancer Trial Change Akeso Stock Narrative
Profile
Akeso, Inc is a publicly listed Chinese biopharmaceutical company that is headquartered in Zhongshan, Guangdong.
It is best known for developing Ivonescimab, a cancer treatment antibody. Wikipedia
About Akeso Inc
CEOMichelle Xia | Michelle Xia
Employees4,08 мың
Founded2012 ж. 19 нау.
Headquarters-
Sector-
Websiteakesobio.com